Proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs. The company’s lead product (LEVADEX) is an orally inhaled migraine therapy.
In March 2013, MAP was acquired by Allergan (NYSE: AGN).
In March 2013, MAP was acquired by Allergan (NYSE: AGN).
Investors 1
| Date | Name | Website |
| - | Bay City C... | baycitycap... |
Mentions in press and media 4
| Date | Title | Description |
| 08.10.2007 | IPO roundup: MAP Pharma’s mixed reception, other recent filings | MAP Pharmaceuticals, the Mountain View, Calif., specialty pharma, had a mixed reception to its IPO Friday. The company priced its shares at $12, below its anticipated range of $14 to $16, raising up to $69 million — substantially less than ... |
| 21.09.2007 | Life sciences briefing: Friday, Sept. 21, 2007 | Featured companies: CG Therapeutics, Complete Genomics, ConforMIS, Flexible Medical Systems, LeMaitre Vascular, MAP Pharmaceuticals, ParaPro, Vascular Architects, Zars Pharma (UPDATED on 10/1/07: See below.) [NOTE: Posting has been slow rec... |
| 19.06.2007 | MAP Pharma charts course for $86M IPO | MAP Pharmaceuticals, a Mountain View, Calif., developer of reformulated drugs for inhalation, filed to raise up to $86 million in an initial public offering. The company’s registration statement with the SEC is here. MAP is the latest drugm... |
| 28.03.2007 | MAP Pharma raises $50M for respiratory and CNS disease treatments | MAP Pharmaceuticals, a Mountain View, Calif, developer of treatments for respiratory and central-nervous-system diseases, said it raised $50 million in a fourth round of venture funding. See statement here. New investor, the D.E. Shaw group... |